Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Go back to Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis| Oppenheimer Rising Dividends Fund, Inc. Class A (NASDAQ: ARDX) | Delayed: 6.37 +0.32 (5.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.05 | 52 Week High | $20.98 | |||
| Open | $6.09 | 52 Week Low | $6.36 | |||
| Day High | $6.42 | P/E | N/A | |||
| Day Low | $6.08 | EPS | $0.00 | |||
| Volume | 4,905,065 | |||||
